What would be your treatment approach in a premenopausal BRCA2+ patient with cT2N0 grade 2-3, ER negative, PR variably positive (30%; staining weak to high), HER2 negative breast cancer?

Would you still treat with neoadjuvant KEYNOTE-522?

Answer from: Medical Oncologist at Academic Institution

Since weakly hormone-positive, HER2-negative breast cancer behaves more similarly to triple-negative breast cancer than strongly hormone receptor-positive breast cancer (Poterala et al., PMID 35676188), I would approach this patient similarly to patients with stage 2 triple-negative breast cancer. I...

Comments

Medical Oncologist at NYU Winthrop Hospital
The patient is not triple negative. She is PR-posi...

Answer from: Medical Oncologist at Academic Institution

Yes, I would treat as TNBC with KN522 and if not a pCR, give adjuvant olaparib with pembro.

Comments

Medical Oncologist at NYU Winthrop Hospital
There is no data to combine pembrolizumab with ola...

Medical Oncologist at H Lee Moffitt Cancer Center, University of South Florida
There is safety and efficacy data from the KEYLYNK...

Answer from: Medical Oncologist at Community Practice

I agree - would treat at TNBC with KN 522

Please select the option that best describes you:

What would be your treatment approach in a premenopausal BRCA2+ patient with cT2N0 grade 2-3, ER negative, PR variably positive (30%; staining weak to high), HER2 negative breast cancer?

Related Questions